König, Alexander Otto

[["dc.bibliographiccitation.firstpage","1280"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Theranostics"],["dc.bibliographiccitation.lastpage","1287"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Berger, Andreas W."],["dc.contributor.author","Schwerdel, Daniel"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Janssen, Klaus-Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Bartsch, Detlef K."],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Staib, Ludger"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Kleger, Alexander"],["dc.contributor.author","Beutel, Alica"],["dc.contributor.author","Schulte, Lucas-Alexander"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Ettrich, Thomas J."],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2019-07-09T11:50:26Z"],["dc.date.available","2019-07-09T11:50:26Z"],["dc.date.issued","2019"],["dc.description.abstract","The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Novel blood-based markers may help to overcome this limitation. Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified. 15 patients with side-branch IPMNs without worrisome features and 32 patients with chronic pancreatitis served for comparison. Logit (logistic regression) models were used to test the performance of single biomarkers and biomarker combinations. Results: CA19-9 and THBS2 alone showed comparable c-statistics of 0.80 and 0.73, respectively, improving to 0.87 when combining these two markers. The c-statistic was further increased to 0.94 when combining CA19-9 and THBS2 with cfDNA quantification. This marker combination performed best for all PDAC stages but also for PDACs grouped by stage. The greatest improvement over CA19-9 was seen in the group of stage I PDAC, from 0.69 to 0.90 for the three marker combination. Conclusion:These data establish the combination of CA19-9, THBS2 and cfDNA as a composite liquid biomarker for non-invasive diagnosis of early-stage PDAC."],["dc.identifier.doi","10.7150/thno.29247"],["dc.identifier.pmid","30867830"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59773"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1838-7640"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4128"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","4128"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Ettrich, Thomas Jens"],["dc.contributor.author","Reinacher-Schick, Anke C."],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Koenig, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Wittel, Uwe A"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Wille, Kai"],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Schimanski, Carl Christoph"],["dc.contributor.author","Prasnikar, Nicole"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Perkhofer, Lukas"],["dc.contributor.author","Berger, Andreas W."],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2020-12-10T18:41:36Z"],["dc.date.available","2020-12-10T18:41:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.4128"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77625"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1298"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Ettrich, Thomas J"],["dc.contributor.author","Berger, Andreas W"],["dc.contributor.author","Perkhofer, Lukas"],["dc.contributor.author","Daum, Severin"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Dickhut, Andreas"],["dc.contributor.author","Wittel, Uwe"],["dc.contributor.author","Wille, Kai"],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Atzpodien, Jens"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Muche, Rainer"],["dc.contributor.author","Prasnikar, Nicole"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2019-07-09T11:49:45Z"],["dc.date.available","2019-07-09T11:49:45Z"],["dc.date.issued","2018"],["dc.description.abstract","Abstract Background Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warranted. A substantial improvement in overall survival of patients with metastatic pancreatic cancer with FOLFIRINOX and nab-paclitaxel/gemcitabine vs standard gemcitabine has been demonstrated in phase III-trials. Indeed nab-paclitaxel/gemcitabine has a more favorable toxicity profile compared to the FOLFIRINOX protocol and appears applicable in a perioperative setting. Methods NEONAX is an interventional, prospective, randomized, controlled, open label, two sided phase II study with an unconnected analysis of the results in both experimental arms against a fixed survival probability (38% at 18 months with adjuvant gemcitabine), NCT02047513. NEONAX will enroll 166 patients with resectable pancreatic ductal adenocarcinoma (≤ cT3, N0 or N1, cM0) in two arms: Arm A (perioperative arm): 2 cycles nab-paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of an 28 day-cycle) followed by tumor surgery followed by 4 cycles nab-paclitaxel/gemcitabine, Arm B (adjuvant arm): tumor surgery followed by 6 cycles nab-paclitaxel/gemcitabine. The randomization (1:1) is eminent to avoid allocation bias between the groups. Randomization is stratified for tumor stage (ct1/2 vs. cT3) and lymph node status (cN0 vs. cN1). Primary objective is disease free survival (DFS) at 18 months after randomization. Key secondary objectives are 3-year overall survival (OS) rate and DFS rate, progression during neoadjuvant therapy, R0 and R1 resection rate, quality of life and correlation of DFS, OS and tumor regression with pharmacogenomic markers, tumor biomarkers and molecular analyses (ctDNA, transcriptome, miRNA-arrays). In addition, circulating tumor-DNA will be analyzed in patients with the best and the worst responses to the neoadjuvant treatment. The study was initiated in March 2015 in 26 centers for pancreatic surgery in Germany. Discussion The NEONAX trial is an innovative study on resectable pancreatic cancer and currently one of the largest trials in this field of research. It addresses the question of the role of intensified perioperative treatment with nab-paclitaxel plus gemcitabine in resectable pancreatic cancers to improve disease-free survival and offers a unique potential for translational research. Trial registration ClinicalTrials.gov : NCT02047513, 08/13/2014."],["dc.identifier.doi","10.1186/s12885-018-5183-y"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15762"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59624"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]